INA’s response to the spread of COVID-19 (SARS-CoV-2) Novel Coronavirus infections in Japan
With the health safety and security of all stakeholders including employees and customers as our top priority, Ina Research (INA) has been implementing measures based on guidance received from government authorities in order to help prevent the spread of COVID-19 (SARS-CoV-2) infections. COVID-19 is the most urgent social concern in the world. However, comparing with European countries and US or China, the COVID-19 infection overshoot has not appeared in Japan as of today (March 25, 2020). Needless to say, we are never off our guard and protection to maintain all contracted studies in operation and all future studies. Animal Rooms: We, INA has highly advanced technologies such as One-by-One Animal
Announcement concerning the start of agency business with ViruSure
Ina Research Inc. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today. (Please refer to the below PDF file for more details.) Announcement concerning the start of agency business with ViruSure GmbH (PDF: 128KB)
株式会社イナリサーチ（以下「当社」）は、海外の試験受託機関（Contract Research Organization 以後「CRO」という）であるViruSure GmbH(オーストリア：以後「オーストリアVS」という)の日本および台湾における代理店業務を開始することを本日決定いたしましたので、お知らせいたします。 （詳細は添付のPDFをご参照下さい）
Agency Agreement with Level Biotechnology Inc., Taiwan
Ina Research Inc. (INA) is pleased to announce the signing of an agency agreement with Level Biotechnology Inc. (LBI), a Taiwanese Contract Research Organization. 1.Market Potential The biopharmaceutical industry in Taiwan is currently growing at an unprecedented rate. With LBI as our locally-based agent, Taiwanese customers can now access INAs services in nonhuman primates, studies which are required as part of the biopharmaceutical development process. In this way, INA hopes to establish a mutually-complementary relationship with LBI, and make inroads into this growing market. 2. About LBI (1) Company Name: Level Biotechnology Inc. (2) Address: No. 80, Lane 169, Kangning St., His-Chih Dist., New Taipei City 221, Taiwan R.O.C. (3)
Level Biotechnology Inc.との代理店契約締結に関するお知らせ
株式会社イナリサーチ（以下「当社」）は、非臨床試験の営業拡大を目的として、台湾の試験受託機関（Contract Research Organization 以後「CRO」という）であるLevel Biotechnology Inc. (以後「台湾LB」という)と代理店契約を締結することを本日決定いたしましたので、お知らせいたします。 （詳細は添付のPDFをご参照下さい） Level Biotechnology Inc.との代理店契約締結に関するお知らせ (PDF形式：107KB)
Tokyo University AMED iD3 Catalyst Unit posted about Grobal SEND Alliance.
A column regarding to the Grobal SEND Alliance (G-SEND) was posted on the website of Tokyo University AMED iD3 Catalyst Unit. G-SEND is a non-profit consortium, consisting of CROs from Japan, South Korea, Taiwan, Singapore, the US and Switzerland. They provide SEND data sets which are created in a standardized process and Ina Reseach is the central CRO as their base. Please see the link below for the article: http://www.id3catalyst.jp/e/column03.html
Analysis Pathology At INA, necropsy and histotechnology are performed by well-trained technicians, and histopathological examinations are performed by certified toxicological pathologists, veterinary pathologists and toxicologists. Furthermore, we schedule regular in-house educational seminars, taught by our esteemed advisor of pathology. Pathology Necropsy Prompt and accurate postmortem examinations Perfusion fixation Specific fixation of organs/tissues Histotechnology Preparation of specimens for light microscopy (routine preparation, serial sections, large sections of the brain, etc.) Preparation of specimens for electron microscopy (TEM) Preparation of frozen sections (cryostat) Special staining (PAS, PAM, iron, Masson trichrome, Azan Maroly, Elastica Van Gieson, fat, etc.) Immunohistochemical staining (immunoenzymatic technique) Histopathology Examinations under light and electron microscopes General toxicity studies Specialty
Clinical Pathology Clinical Pathology A wide range of clinical pathology services are available at INA, conducted by experienced veterinarians (certified clinical chemists) and medical technologists. Clinical Pathology Hematology Simultaneous evaluation of complete blood counts (red blood cell counts, white blood cell counts, platelet counts, hemoglobin and hematocrit measurements), white blood cell differential counts and reticulocyte counts/ratios using a hematoanalyzer). Microscopic measurement of reticulocytes by supravital staining and calculation of white blood cell differential (ratio) in blood smears. Blood coagulation/fibrinolysis Measurements of prothrombin time, activated partial thromboplastin time, fibrinogen and coagulation factor activities using a coagulator. D-dimer and fibrin/fibrinogen degradation product (FDP) measurements using commercial reagents. Measurement of platelet aggregation ability.
Analysis Clinical Pathology A wide range of clinical pathology services are available at INA, conducted by experienced veterinarians (certified clinical chemists) and medical technologists. Pathology At INA, necropsy and histotechnology are performed by well-trained technicians, and histopathological examinations are performed by certified toxicological pathologists, veterinary pathologists and toxicologists. Furthermore, we schedule regular in-house educational seminars, taught by our esteemed advisor of pathology. Metabolism & Chemical Analysis INA offers analyses of test article and dosing formulations, as well as drug concentrations in biological samples. We also offer in vitro and in vivo analysis of hepatic drug-metabolizing enzymes and metabolizing enzyme gene expressions (mRNA).
Health Food Studies
Health Food Studies Non-clinical Studies Efficacy Studies Below are some examples of the disease model animals available for food efficacy studies. INA also offers free advice and study design planning. Improvement of insulin resistance Reductive effects in hyperlipemia model animals Reductive effects in hypertensive model animals Bone loss inhibitory effects in ovariectomized osteoporosis models and osteopenia models prepared by sciatic neurectomy Improvements to arthritis in arthrorheumatism model animals Antitumor effects Antistress effects Safety Studies All studies are GLP compliant and follow the relevant toxicity study guidelines for pharmaceuticals, as well as Japanese government regulations regarding Food for Specified Health Use (FOSHU, 1998 ). Single dose toxicity Repeated dose toxicity Genotoxicity